Safety and Tolerability of PCSK9 Inhibitors: Current Insights

The current era of preventive cardiology continues to emphasize on low-density lipoprotein cholesterol (LDL-C) reduction to alleviate the burden of atherosclerotic cardiovascular disease (ASCVD). In this regard, the pharmacological inhibition of proprotein convertase subtilisin/kexin type 9 (PCSK9)...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Clin Pharmacol
Autors principals: Kosmas, Constantine E, Skavdis, Andreas, Sourlas, Andreas, Papakonstantinou, Evangelia J, Peña Genao, Edilberto, Echavarria Uceta, Rogers, Guzman, Eliscer
Format: Artigo
Idioma:Inglês
Publicat: Dove 2020
Matèries:
Review
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7737942/
https://ncbi.nlm.nih.gov/pubmed/33335431
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/CPAA.S288831
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars